ライフサイエンスコーパス: idazoxan

1 of the alpha2 adrenergic receptor antagonist idazoxan.

2 um rats after administration of yohimbine or idazoxan.

3 of the analgesic effect by pretreatment with idazoxan.

4 srupted mothering of dams given yohimbine or idazoxan.

5 ), nisoxetine (2, 4, 8 micrograms/side), and idazoxan (0.25, 1, 4 micrograms/side) all decreased the

6 tion was blocked by the alpha 2-antagonists, idazoxan (1 microM) and yohimbine (1 microM).

7 f the alpha 2-adrenergic receptor antagonist idazoxan (1.0 microgram.kg-1.min-1 IC) before and after

8 Idazoxan (10 microM) significantly increased basal NA re

9 olamine (10 microM) or the alpha2-antagonist idazoxan (2 microM).

10 ands (phenyzoline, tracizoline, RS45041, and idazoxan, 3.2-75 mg/kg, i.p.) all occasioned > 80% CR405

11 The effect was prevented by idazoxan (5 mg/kg, i.p.), an imidazoline/alpha(2)-adreno

12 nt nanoinjection of the alpha2-AR antagonist idazoxan (6 nmol) into the rRPa reversed the clonidine-e

13 fects that were reversed by nanoinjection of idazoxan (6 nmol) into the rRPa.

14 Idazoxan, a mixed antagonist of imidazoline and alpha-2

15 sin (an alpha1 antagonist, 4 mg/kg), but not idazoxan (an alpha2 antagonist, 1 mg/kg), administered i

16 ration of the alpha2-adrenoceptor antagonist idazoxan and intra-LC co-injection of the AMPA antagonis

17 uring exercise in the absence of a stenosis, idazoxan and LNNA had no effect on coronary blood flow.

18 iking difference in inverse efficacy between idazoxan and RX821002 may account for in vivo pharmacolo

19 The alpha2 antagonist idazoxan and the beta antagonist propranolole, however,

20 azosin, the alpha 2-adrenoceptor antagonists idazoxan and yohimbine, the noradrenaline-depleting drug

21 lline, 6-cyano-7-nitroquinoxaline-2,3-dione, idazoxan, and strychnine, suggesting that this activity

22 e control period and after administration of idazoxan before and after LNNA.

23 nists targeting alpha2-adrenergic receptors (idazoxan), beta-adrenergic receptor (beta-AR) (propranol

24 pha2-antagonists, yohimbine, rauwolscine and idazoxan blocked NE-induced inhibition in all neurons te

25 behavior after BSTv infusion of yohimbine or idazoxan cannot both be readily explained by an increase

26 gide and MDL 72222 partially antagonized and idazoxan completely antagonized A-85380-induced antinoci

27 However, BSTv infusion of idazoxan did not reproduce yohimbine's anxiogenic effect

28 With no change in distal coronary pressure, idazoxan had no effect on mean myocardial blood flow in

29 Binding of idazoxan (IDA) to imidazoline receptors of the I2 subtyp

30 onidine (CLON) and of the alpha 2 antagonist idazoxan (IDA) were made over 1 min through cannulae in

31 ol), and half received the alpha2 antagonist idazoxan (IDA; 0.33 nmol).

32 y artery stenosis after LNNA administration, idazoxan increased mean myocardial blood flow to 0.62 +/

33 The alpha2 antagonist idazoxan increased spike frequency, suggesting tonic NE-

34 Neither idazoxan nor LNNA altered any of the systemic hemodynami

35 stimulation of the locus coeruleus (2 microM idazoxan or 2 mM acetylcholine) paired with odor produce

36 pha-adrenergic agonists tetrahydrozoline and idazoxan produced monodiazeniumdiolated amidine zwitteri

37 The alpha2-AR antagonists yohimbine and idazoxan reduced clonidine's effect on V1/2 and on the I

38 re selective alpha2-autoreceptor antagonist, idazoxan (Smith et al., 2012).

39 However, when idazoxan was infused during exercise in the presence of

40 > RX821002 > MK912, whereas phentolamine and idazoxan were essentially neutral antagonists.